COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference
28/02/2019
THE WOODLANDS, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from two posters highlighting XERMELO ® (telotristat ethyl) will be presented at the [...]
Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
28/02/2019
SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]
IMV Inc. dépose un supplément de prospectus provisoire dans le cadre d’un projet d’appel public à l’épargne visant des actions ordinaires
28/02/2019
DARTHMOUTH, Nouvelle-Écosse, 28 févr. 2019 (GLOBE NEWSWIRE) -- IMV Inc. (« IMV » ou la « société ») (NASDAQ : IMV; TSX : IMV), société de recherche clinique en immuno‑oncologie, dépose aujourd’hui un supplément de [...]
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
28/02/2019
DARTMOUTH, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has today filed a preliminary prospectus supplement [...]
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
28/02/2019
GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of [...]
Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2018 Operating Results
28/02/2019
2018 Revenue of $204.3 million, growth of 53%; 4Q 2018 Revenue of $57.3 million, growth of 32% Provides initial 2019 financial outlook MOORESTOWN, N.J., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“ [...]
The Board of Directors of Xbrane has resolved on a fully guaranteed rights issue of up to approximately SEK 60 million
28/02/2019
Press release 28 February 2019 The Board of Directors in Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today, pursuant to the authorization granted by the annual general meeting on 24 May 2018, resolved on [...]
Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results
28/02/2019
REDWOOD CITY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2018. [...]
Geron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
28/02/2019
MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, [...]
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
28/02/2019
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three [...]
Adverum to Present at the Cowen 39th Annual Health Care Conference
28/02/2019
MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the [...]
Aravive to Report Fourth Quarter and Full Year 2018 Financial Results and Corporate Updates on March 7, 2019
28/02/2019
HOUSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced the company plans to report financial results for the fourth quarter and full year 2018 and [...]
CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
28/02/2019
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for [...]
ICU Medical, Inc. Announces Fourth Quarter 2018 Results
28/02/2019
SAN CLEMENTE, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care [...]
SI-BONE to Present at the Canaccord Genuity Musculoskeletal Conference
28/02/2019
SANTA CLARA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse [...]
Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
28/02/2019
Fourth Quarter 2018 Results : Revenue totals $5.7 million, growing 33% year over year Billable tests delivered total 6,408, growing 52% year over year GAAP loss of $935,000, or $0.05 per share Non-GAAP loss of $193,000 [...]
Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
28/02/2019
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million. Elacestrant’s Phase 3 [...]
KemPharm Reports Q4 and FY 2018 Results
28/02/2019
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse potential programs Received approval [...]
HealthEquity Sets Date to Announce Year-end Results
28/02/2019
Attend Investor Conference DRAPER, Utah, Feb. 28, 2019 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent HSA custodian, today announced that it plans to [...]

Pages